Browse > Article
http://dx.doi.org/10.14405/kjvr.2013.53.2.083

Field evaluation of Enterotoxigenic Escherichia coli-specific bacteriophage (ΦCJ19) as a feed additive  

Yoo, Anna (College of Veterinary Medicine, Seoul National University)
Cha, Seung Bin (College of Veterinary Medicine, Seoul National University)
Shin, Min Kyoung (College of Veterinary Medicine, Seoul National University)
Park, Hong Tae (College of Veterinary Medicine, Seoul National University)
Seo, Hyo Sil (Research Institute of Biotechnology, CJ Cheil Jedang Co.)
Kim, Jae Won (Research Institute of Biotechnology, CJ Cheil Jedang Co.)
Yoo, Han Sang (College of Veterinary Medicine, Seoul National University)
Publication Information
Korean Journal of Veterinary Research / v.53, no.2, 2013 , pp. 83-88 More about this Journal
Abstract
Field efficacy of enterotoxigenic Escherichia coli-specific phage (${\Phi}CJ19$) as a feed additive was evaluated in weaning piglets. Fifty-four piglets at 3-4 weeks old were allocated in three different groups and two of them were fed with bacteriophage at different concentrations ($10^6PFU/kg$ feed and $10^8PFU/kg$ feed, respectively) for 30 days. Body weight and feed intake were measured at 10 days interval and body condition and fecal score were inspected every day. Based on the measurement, feed conversion rate (FCR) and average daily gain (ADG) of each group during 30 days were analyzed. The analysis suggests that the bacteriophage may help the improvement of FCR and ADG at $10^8PFU/kg$ of bacteriophage feeding group in 30 days. A result from analysis of fecal score indicates that the bacteriophage also may help to relieve the intermittent diarrhea in post-weaning stage. Those results suggest that bacteriophage might help the growth of piglets in post-weaning stage.
Keywords
bacteriophage; enterotoxigenic Escherichia coli; feed additive; field efficacy;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Adams MH. Bacteriophages. pp. 18-592, Interscience Publishers, New York, 1959.
2 Bertani G. Lysogenic versus lytic cycle of phage multiplication. Cold Spring Harb Symp Quant Biol 1953, 18, 65-70.   DOI
3 Cha SB, Rayamajhi N, Lee WJ, Shin MK, Roh YM, Jung MH, Myoung KS, Ahn YT, Huh CS, Yoo HS. Evaluation of in vitro and in vivo bacteriophage efficacy against Salmonella enterica serovar Enteritidis infection. Korean J Vet Res 2010, 50, 213-220.
4 Cha SB, Yoo AN, Lee WJ, Shin MK, Jung MH, Shin SW, Cho YW, Yoo HS. Effect of bacteriophage in Enterotoxigenic Escherichia coli (ETEC) infected pigs. J Vet Med Sci 2012, 74, 1037-1039.   DOI   ScienceOn
5 Chernomordik AB. Bacteriophages and their therapeuticprophylactic use. Med Sestra 1989, 48, 44-47.
6 Chibani-Chennoufi S, Sidoti J, Bruttin A, Kutter E, Sarker S, Brussow H. In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy. Antimicrob Agents Chemother 2004, 48, 2558-2569.   DOI   ScienceOn
7 d'Herelle F. Bacteriophage as a treatment in acute medical and surgical infections. Bull N Y Acad Med 1931, 7, 329-348.
8 Dibner JJ, Richards JD. Antibiotic growth promoters in agriculture: history and mode of action. Poult Sci 2005, 84, 634-643.   DOI
9 Gaastra W, de Graaf FK. Host-specific fimbrial adhesins of noninvasive enterotoxigenic Escherichia coli strains. Microbiol Rev 1982, 46, 129-161.
10 Guttman B, Raya R, Kutter E. Basic phage biology. In: Kutter E, Sulakvelidze A (eds.). Bacteriophages Biology and Applications. 1st ed. pp. 28-66, CRC Press, Boca Raton, 2005.
11 Jamalludeen N, Johnson RP, Shewen PE, Gyles CL. Evaluation of bacteriophages for prevention and treatment of diarrhea due to experimental enterotoxigenic Escherichia coli O149 infection of pigs. Vet Microbiol 2009, 136, 135-141.   DOI   ScienceOn
12 Kim SJ, Kim JD, Yang SY, Kim NH, Lee CH, Yang DS, Han JH. Evaluation of bacteriophages for prevention and treatment of diarrhea due to experimental enterotoxigenic Escherichia coli K88 infection of weaned piglets. Korean J Vet Serv 2011, 34, 341-352.   DOI   ScienceOn
13 Koluman A, Dikici A. Antimicrobial resistance of emerging foodborne pathogens: Status quo and global trends. Crit Rev Microbiol 2013, 39, 57-69.   DOI   ScienceOn
14 Kropinski AM. Phage therapy - Everything old is new again. Can J Infect Dis Med Microbiol 2006, 17, 297-306.
15 Kudva IT, Jelacic S, Tarr PI, Youderian P, Hovde CJ. Biocontrol of Escherichia coli O157 with O157-specific bacteriophages. Appl Environ Microbiol 1999, 65, 3767-3773.
16 Kutateladze M, Adamia R. Phage therapy experience at the Eliava Institute. Med Mal Infect 2008, 38, 426-430.   DOI   ScienceOn
17 Levine MM. Escherichia coli that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent. J Infect Dis 1987, 155, 377-389.   DOI   ScienceOn
18 Merril CR, Scholl D, Adhya SL. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2003, 2, 489-497.   DOI   ScienceOn
19 Noamani BN, Fairbrother JM, Gyles CL. Virulence genes of O149 enterotoxigenic Escherichia coli from outbreaks of postweaning diarrhea in pigs. Vet Microbiol 2003, 97, 87-101.   DOI   ScienceOn
20 Sheng H, Knecht HJ, Kudva IT, Hovde CJ. Application of bacteriophages to control intestinal Escherichia coli O157:H7 levels in ruminants. Appl Environ Microbiol 2006, 72, 5359-5366.   DOI   ScienceOn
21 Summers WC. Bacteriophage research: early history. In: Kutter E, Sulakvelidze A (eds.). Bacteriophages Biology and Applications. 1st ed. pp. 5-27, CRC Press, Boca Raton, 2005.
22 Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 1982, 128, 307-318.
23 Smith HW, Huggins MB. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen Microbiol 1983, 129, 2659-2675.
24 Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob Agents Chemother 2001, 45, 649-659.   DOI   ScienceOn
25 Weber-Dabrowska B, Mulczyk M, Gorski A. Bacteriophage therapy of bacterial infections: an update of our institute's experience. Arch Immunol Ther Exp (Warsz) 2000, 48, 547-551.